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aBStract
CONTEXT AND OBJECTIVE: Lumiracoxib is an anti-inflammatory drug that has been used to treat 
acute dental pain, mainly in postsurgical settings, in which the greatest levels of pain and discomfort 
are experienced during the first 24 hours. This study aimed to assess the efficacy and safety of lumira-
coxib for treating acute postsurgical dental pain. 
DESIGN AND SETTING: Systematic review developed at the Brazilian Cochrane Centre, Universidade 
Federal de São Paulo. 
METHODS: An electronic search was conducted in the PubMed, Cochrane Library, Lilacs (Literatura 
Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library Online) 
and Embase databases. A manual search was also performed. Only randomized controlled trials were 
included, and these were selected and assessed by two researchers with regard to the risk of bias. 
RESULTS: Three clinical trials with 921 participants were included. Lumiracoxib 400 mg produced 
onset of analgesia in a shorter time than shown by lumiracoxib 100 mg, celecoxib 200 mg and ibu-
profen 400 mg. There was no difference between lumiracoxib 400 mg and rofecoxib 50 mg. In two 
studies, the mean time taken to attain onset of analgesia for the placebo was not estimated because 
the number of participants who reached onset was too small.  
CONCLUSION: There is evidence with a moderate risk of bias that recommends the use of lumira-
coxib for acute postoperative dental pain. However, the adverse effects are not completely known. 
Given that lumiracoxib is currently available in only three countries, further studies are likely to be 
rare and discouraged. 
reSUmO
CONTEXTO E OBJETIVO: O lumiracoxibe é um anti-inflamatório que tem sido utilizado no tratamen-
to de dor dental aguda, principalmente no cenário pós-cirúrgico, no qual níveis mais elevados de 
dor e desconforto são sentidos durante as primeiras 24 horas. Este estudo teve por objetivo avaliar a 
eficácia e a segurança do lumiracoxibe no tratamento da dor dental aguda e pós-operatória.
TIPO DE ESTUDO E LOCAL: Revisão sistemática desenvolvida no Centro Cochrane do Brasil, Univer-
sidade Federal de São Paulo. 
MÉTODOS: Foi realizada busca eletrônica nas bases de dados PubMed, Cochrane Library, Lilacs (Li-
teratura Latino-Americana e do Caribe em Ciências da Saúde), SciELO (Scientific Electronic Library 
Online) e Embase. Também foi realizada busca manual. Apenas ensaios clínicos randomizados foram 
incluídos e foram selecionados e avaliados por dois pesquisadores quanto ao risco de viés.
RESULTADOS: Foram incluídos três ensaios clínicos com 921 participantes. O lumiracoxibe 400 mg 
mostrou menor tempo de início de analgesia que o lumiracoxibe 100 mg, celecoxibe 200 mg e ibu-
profeno de 400 mg. Não houve diferença entre lumiracoxibe 400 mg e rofecoxibe 50 mg. Em dois 
estudos o tempo médio de início de analgesia para o placebo não foi estimado, pois o número de 
participantes que a alcançou foi pequeno.
CONCLUSÃO: Há evidências, com moderado risco de viés, que recomendam o uso de lumiracoxibe 
para a dor dental aguda e pós-operatória. No entanto, os efeitos adversos não são completamente 
conhecidos. Considerando que o lumiracoxibe está disponível em apenas três países, provavelmente 
a realização de pesquisas futuras será rara e desestimulada.
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INTRODUCTION
Pain is an unpleasant sensory and emotional experience asso-
ciated with actual or potential tissue damage, or described in 
terms of such damage. Acute pain is elicited by substantial 
injury of body tissue and activation of nociceptive transducers 
at the site of local tissue damage. This type of pain is also seen 
after trauma, surgical interventions and some diseases.1 Also in 
dentistry, this pain may be associated with a pathological con-
dition or a surgical intervention. Among the most common 
causes for acute toothache of pathological origin are acute pulp 
pain and acute periodontal pain. Acute pulp pain may come 
from dental exposure or from bacterial infection in the dental 
pulp. Periodontal acute pain is usually due to acute apical peri-
odontitis resulting from trauma or extension of pulp inflamma-
tion inwards to apical tissues, or may be due to acute periodon-
tal abscess or acute periodontitis, usually of bacterial origin.2 
Among dental procedures, surgical removal of wisdom teeth 
and periodontal surgical procedures are the ones most expected 
to cause postoperative pain.3 
Acute dental pain and postoperative pain are often treated 
with analgesics and non-steroidal anti-inflammatory drugs 
(NSAIDs) such as paracetamol, ibuprofen, rofecoxib and 
celecoxib.4-6 The efficacy of these drugs in reducing inflamma-
tion and pain is largely attributed to prevention of prostaglandin 
synthesis via non-specific inhibition of both cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2).5 
Lumiracoxib is a new selective inhibitor of COX-2 that was 
also developed for treating acute pain. COX-2 inhibitors have 
been developed to avoid COX-1 related gastrointestinal prob-
lems.7 Lumiracoxib is structurally distinct from other COX-2 
selective inhibitors; it has demonstrated good oral bioavailabil-
ity (74%), rapid absorption and a relatively short plasma half-
life of 3-6 hours. In spite of the relatively short half-life, studies 
have shown that lumiracoxib administered once daily provides 
24-hours analgesic efficacy.5 It has been postulated that the anal-
gesic actions of NSAIDs result from inhibition of peripheral syn-
thesis of prostaglandins, which are formed secondarily to tis-
sue injury and inflammation by the enzyme cyclooxygenase.8 
Patients who have undergone dental surgery report high levels 
of pain and discomfort during the first 24 hours.5,6 It is therefore 
essential that any analgesic agent used to treat postoperative pain 
should have rapid onset of action on the first day following den-
tal surgery.
Lumiracoxib is currently available in three countries, 
and the permitted doses are restricted to short prescrip-
tions. Therefore, this study assessed the effects of lumira-
coxib in relieving acute postoperative dental pain in an 
attempt to provide dentists with a drug for which dosing and 
ideal action timing information are available, and also safety 
information for patients.
OBJECTIVES
To develop a systematic review assessing the efficacy and safety of 
lumiracoxib for treating acute postoperative dental pain.
METHODS
This systematic review was developed at the Brazilian Cochrane 
Center and within the Postgraduate Program on Internal and 
Therapeutic Medicine at Universidade Federal de São Paulo 
(Unifesp), after receiving approval from the local Ethics Com-
mittee. The review and meta-analysis were conducted in accor-
dance with the Cochrane Collaboration Handbook.8 
Data sources and searches
The following electronic databases were searched: CENTRAL 
(Cochrane Central Register of Controlled Trials), PubMed 
(1966 to present), Embase (1980 to present), Lilacs (Literatura 
Latino-Americana e do Caribe em Ciências da Saúde, 1982 to 
present), SciELO (Scientific Electronic Library Online), the 
Cochrane Oral Health Group’s Specialized Register and the 
Cochrane Pain, Palliative and Supportive Care Specialized Reg-
ister. A general search strategy was used, with adaptations to the 
characteristics of each database. The search strategies used are 
presented in Table 1. 
For the manual search, thesis databases, references lists of the 
relevant studies and clinical trials register databases were taken 
into account. Specialists in the field, authors of the trials included 
and pharmaceutical companies were contacted in order to try to 
obtain unpublished or missing data.
There was no language restriction.
Randomized clinical trials were included. In these trials, 
the participants were adults suffering from acute postoperative 
pain who received lumiracoxib (either separately or in associ-
ation), regardless of the dosage, and the use of this drug was 
compared with other interventions, such as anti-inflammatory 
drugs, analgesics or placebo. The trials included needed to eval-
uate improvement of pain as an outcome, regardless of the tool 
used to assess this.
Study selection
Study selection was performed independently by two review-
ers (RS and RR), in order to identify and select studies that met 
the inclusion criteria for this review. Agreement was reached by 
consensus after analysis of the complete text of the study, and 
after contact with study authors for further information, when 
needed.
Data extraction and risk-of-bias assessment
Two authors (RS and RR) independently extracted the data and 
used a standard form to organize the following information 
regarding each study included: title, publication data, authors, 
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number and characteristics of the participants, interventions, 
outcomes and potential conflicts of interests among the authors 
involved in the trial. 
The risks of bias of the trials included were measured inde-
pendently by two reviewers using the risk-of-bias table devel-
oped by the Cochrane Collaboration, which is available in the 
Cochrane Handbook.9 Six domains were assessed: sequence 
generation, allocation concealment, blinding of participants, 
personnel and outcome assessors, incomplete outcome data, 
freedom from selective reporting and other sources of bias. 
These domains were classified as “Yes” (i.e. low risk of bias), 
“Unclear” (uncertain risk of bias) or “No” (i.e. high risk of 
bias). The overall classification of each study was based on the 
three main domains as follows: sequence generation, alloca-
tion concealment and blinding, as stated in the Handbook for 
Systematic Reviews.9
The evaluations were compared and any inconsistencies 
between the review authors in interpreting the inclusion criteria 
and their significance for the trials selected were discussed and 
resolved. The study authors were contacted in cases of missing 
data or uncertainty over any data.
Data analysis 
The Review Manager software 5.0 (Cochrane Collaboration) 
was used to produce the graphs. For dichotomous outcomes, the 
intervention estimates were expressed as relative risks together 
with 95% confidence intervals. For continuous outcomes, mean 
differences and 95% confidence intervals were used to summa-
rize the data for each trial. 
Since it was not possible to produce any meta-analysis, consid-
ering that the three studies included were heterogeneous in rela-
tion to comparison groups, outcomes assessed or tools applied, 
heterogeneity and sensitivity analyses were not carried out. 
RESULTS
Through the search strategy, 279 articles were found. From these, 
based on the inclusion criteria, only four were selected. There was 
one case of duplicated publication, and therefore one clinical trial 
was excluded (study by Schnitzer).10
The first study included, with 202 patients, presented four 
arms and compared lumiracoxib 400 mg or 100 mg with ibupro-
fen 400 mg and placebo.6 The second one compared lumiracoxib 
400 mg with rofecoxib 50 mg, celecoxib 200 mg and placebo, and 
Table 1. Search strategies for electronic database
Database Search strategy
Cochrane Library 
1. lumiracoxib 
2. prexige 
3. OR/1-2 
4. Exp PAIN (MeSH term) 
5. pain$ 
6. toothache$ 
7. odontalgi$ 
8. OR/4-7 
9. SURGERY, ORAL (MeSH term) 
10. Exp ORAL SURGICAL PROCEDURES (MeSH term) 
11. (“oral surgical” or “oral surgery” or (dental AND (surgery or surgical))) 
12. (apicectom$ or apicoectom$ or (osteotom$ AND (mandib$ or maxilla$))) 
13. ((tooth adj6 extract$) or “dental extract$” or (extract$ adj6 teeth)) 
14. MOLAR, THIRD (MeSH term) 
15. ((third adj3 molar$) or third-molar$)) 
16. “wisdom tooth” or “wisdom teeth” 
17. OR/14-16 
18. 9 or 10 or 11 or 12 or 13 or 17 
19. 3 AND 8 AND 18 (records retrieved = 9 records? test group 1)
20. “COX 189” or COX-189 
21. CYCLOOXYGENASE 2 INHIBITORS (MeSH term) 
22. “COX-2 inhibitor$” or “cyclooxygenase 2 inhibitor$” 
23. OR/20-22
24. (3 OR 23) AND 8 AND 18 (records retrieved = 73) (24 NOT 19 = 64 records test group 2) 
25. exp CYCLOOXYGENASE INHIBITORS (MeSH term)
26. CYCLOOXYGENASE INHIBITORS (MeSH term) 
27. cyclooxygenase inhibitor$ 
28. OR/26-27 
29. (3 OR 23 OR 28) AND 8 AND 18 (records retrieved = 105) (29 NOT 24 = 32 records test group 3)  
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Table 1 - Continuation
Database Search strategy
Embase 
1. lumiracoxib 
2. prexige 
3. OR/1-2 
4. Exp PAIN (MeSH term) 
5. pain$ 
6. toothache$ 
7. odontalgi$ 
8. OR/4-7 
9. SURGERY, ORAL (MeSH term) 
10. Exp ORAL SURGICAL PROCEDURES (MeSH term) 
11. (“oral surgical” or “oral surgery” or (dental AND (surgery or surgical))) 
12. (apicectom$ or apicoectom$ or (osteotom$ AND (mandib$ or maxilla$))) 
13. ((tooth adj6 extract$) or “dental extract$” or (extract$ adj6 teeth))
14. MOLAR, THIRD (MeSH term) 
15. ((third adj3 molar$) or third-molar$)) 
16. “wisdom tooth” or “wisdom teeth” 
17. OR/14-16 
18. 9 or 10 or 11 or 12 or 13 or 17 
19. 3 AND 8 AND 18 (records retrieved = 9 records? test group 1)
20. “COX 189” or COX-189 
21. CYCLOOXYGENASE 2 INHIBITORS (MeSH term) 
22. “COX-2 inhibitor$” or “cyclooxygenase 2 inhibitor$” 
23. OR/20-22 
24. (3 OR 23) AND 8 AND 18 (records retrieved = 73)   (24 NOT 19 = 64 records test group 2) 
25. exp CYCLOOXYGENASE INHIBITORS (MeSH term) 
26. CYCLOOXYGENASE INHIBITORS (MeSH term) 
27. cyclooxygenase inhibitor$ 
28. OR/26-27 
29. (3 OR 23 OR 28) AND 8 AND 18 (records retrieved = 105) (29 NOT 24 = 32 records test group 3)  
AND  
1. Randomized controlled trial/ 
2. Controlled study/ 
3. Randomization/ 
4. Double blind procedure/ 
5. Single blind procedure/ 
6. Clinical trial/ 
7. (clinical adj5 trial$).ti,ab,hw 
8. ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw 
9. Placebo/ 
10. Placebo$.ti,ab,hw 
11. Random$.ti,ab,hw 
12. Methodology.sh 
13. latin square.ti,ab,hw 
14. crossover.ti,ab,hw 
15. cross-over.ti,ab,hw 
16. Crossover Procedure/ 
17. Drug comparison/ 
18. Comparative study/ 
19. (comparative adj5 trial$).ti,ab,hw 
20. (control$ or prospectiv$ or volunteer$).ti,ab,hw 
21. exp “Evaluation and Follow Up”/
22. Prospective study/ 
23. or/1-22 24. animal/ not (human/ and animal/)25.23 not 24 
24. animal/ not (human/ and animal/)
25. 23 not 24
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Database Search strategy
Lilacs (Literatura Latino-
Americana e do Caribe 
em Ciência da Saúde)
(prexige) OR (LUMIRACOXIB) OR (LUMIRACOXIB  COX 189 ) OR (COX-189) OR (lumiracoxib) OR (COX-2 inhibitor) OR (Organic 
Chemicals) OR (“Cyclooxygenase 2 Inhibitors)
(Toothache) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR (acute dental 
pain)
PubMed
(“prexige “[Substance Name]) OR (LUMIRACOXIB) OR (LUMIRACOXIB  COX 189 ) OR (COX-189) OR (lumiracoxib) OR (COX-2 
inhibitor) OR (“Organic Chemicals”[Mesh]) OR (“Cyclooxygenase 2 Inhibitors “[Pharmacological Action]) or (Cyclooxygenase  
Inhibitors)
AND
(“Toothache”[Mesh]) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR 
(acute dental pain) or (dental pain  postoperative)
AND
randomized controlled trial [Publication Type] OR controlled clinical trial [Publication Type] OR randomized controlled trials 
[MeSH Terms] OR random allocation [MeSH Terms] OR double blind method [MeSH Terms] OR single blind method [MeSH 
Terms] OR clinical trial [Publication Type] OR clinical trials [MeSH Terms] OR (clinical* [Text Word] AND trial* [Text Word]) OR 
single* [Text Word] OR double* [Text Word] OR treble* [Text Word] OR triple* [Text Word] OR placebos [MeSH Terms] OR 
placebo* [Text Word] OR random* [Text Word] OR research design [MeSH Terms] OR comparative study [MeSH Terms] OR 
evaluation studies [MeSH Terms] OR follow-up studies [MeSH Terms] OR prospective studies [MeSH Terms] OR control* [Text 
Word] OR prospectiv* [Text Word] OR volunteer* [Text Word]
SciELO
(prexige) OR (LUMIRACOXIB) OR (LUMIRACOXIB  COX 189 ) OR (COX-189) OR (lumiracoxib) OR (COX-2 inhibitor) OR (Organic 
Chemicals) OR (“Cyclooxygenase 2 Inhibitors)
AND
(Toothache) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR (acute dental 
pain)
Cochrane Library 
1. lumiracoxib
2. prexige 
3. OR/1-2 
4. Exp PAIN (MeSH term) 
5. pain$ 
6. toothache$ 
7. odontalgi$ 
8. OR/4-7 
9. SURGERY, ORAL (MeSH term) 
10. Exp ORAL SURGICAL PROCEDURES (MeSH term) 
11. (“oral surgical” or “oral surgery” or (dental AND (surgery or surgical))) 
12. (apicectom$ or apicoectom$ or (osteotom$ AND (mandib$ or maxilla$))) 
13. ((tooth adj6 extract$) or “dental extract$” or  (extract$ adj6 teeth)) 
14. MOLAR, THIRD (MeSH term) 
15. ((third adj3 molar$) or third-molar$)) 
16. “wisdom tooth” or “wisdom teeth” 
17. OR/14-16 
18. 9 or 10 or 11 or 12 or 13 or 17 
19. 3 AND 8 AND 18 (records retrieved = 9 records? test group 1) 
20. “COX 189” or COX-189 
21. CYCLOOXYGENASE 2 INHIBITORS (MeSH term) 
22. “COX-2 inhibitor$” or “cyclooxygenase 2 inhibitor$” 
23. OR/20-22
24. (3 OR 23) AND 8 AND 18 (records retrieved = 73) (24 NOT 19 = 64 records test group 2)
25. exp CYCLOOXYGENASE INHIBITORS (MeSH term)
26. CYCLOOXYGENASE INHIBITORS (MeSH-0 term)
27. cyclooxygenase inhibitor$
28. OR/26-27 29. (3 OR 23 OR 28) AND 8 AND 18 (records retrieved = 105) (29 NOT 24 = 32 records test group 3)
Table 1 - Continuation
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Database Search strategy
Embase 
1. lumiracoxib 
2. prexige 
3. OR/1-2 
4. Exp PAIN (MeSH term) 
5. pain$ 
6. toothache$ 
7. odontalgi$ 
8. OR/4-7 
9. SURGERY, ORAL (MeSH term) 
10. Exp ORAL SURGICAL PROCEDURES (MeSH term) 
11. (“oral surgical” or “oral surgery” or (dental AND (surgery or surgical))) 
12. (apicectom$ or apicoectom$ or (osteotom$ AND (mandib$ or maxilla$))) 
13. ((tooth adj6 extract$) or “dental extract$” or  (extract$ adj6 teeth)) 
14. MOLAR, THIRD (MeSH term) 
15. ((third adj3 molar$) or third-molar$)) 
16. “wisdom tooth” or “wisdom teeth” 
17. OR/14-16 18. 9 or 10 or 11 or 12 or 13 or 17 19. 3 AND 8 AND 
18 (records retrieved = 9 records? test group 1) 
19. 3 AND 8 AND 18 (records retrieved = 9 records? test group 1)
20. “COX 189” or COX-189 
21. CYCLOOXYGENASE 2 INHIBITORS (MeSH term) 
22. “COX-2 inhibitor$” or “cyclooxygenase 2 inhibitor$” 
23. OR/20-22 
24. (3 OR 23) AND 8 AND 18 (records retrieved = 73) (24 NOT 19 = 64 records test group 2) 
25. exp CYCLOOXYGENASE INHIBITORS (MeSH term) 
26. CYCLOOXYGENASE INHIBITORS (MeSH term) 
27. cyclooxygenase inhibitor$ 
28. OR/26-27 
29. (3 OR 23 OR 28) AND 8 AND 18 (records retrieved = 105) (29 NOT 24 = 32 records test group 3)  
AND  
1. Randomized controlled trial/ 
2. Controlled study/ 
3. Randomization/ 
4. Double blind procedure/ 
5. Single blind procedure/ 
6. Clinical trial/ 
7. (clinical adj5 trial$).ti,ab,hw 
8. ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw 
9. Placebo/  
10. Placebo$.ti,ab,hw 
11. Random$.ti,ab,hw 
12. Methodology.sh 
13. latin square.ti,ab,hw 
14. crossover.ti,ab,hw 
15. cross-over.ti,ab,hw 
16. Crossover Procedure/ 
17. Drug comparison/ 
18. Comparative study/ 
19. (comparative adj5 trial$).ti,ab,hw 
20. (control$ or prospectiv$ or volunteer$).ti,ab,hw 
21. exp "Evaluation and Follow Up"/
22. Prospective study/ 
23. or/1-22 
24. animal/ not (human/ and animal/) 
25. 23 not 24
Table 1 - Continuation
Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials | SyStematic review
Sao Paulo Med J. 2011; 129(5):335-45     341
assessed 355 patients.5 The third compared lumiracoxib 400 mg 
with celecoxib 400 mg and placebo, and assessed 364 patients.4 
These studies were all carried out in the United States with finan-
cial support from the pharmaceutical industry. The overall flow 
chart of the studies is presented in Figure 1.
The efficacy outcomes that it was initially proposed to assess 
through these trials were: time taken to onset of analgesia, over-
all evaluation score, relief of pain on visual analogue scale (VAS), 
four-point category scale pain, summed (time-weighted) pain 
intensity difference (SPID), pain relief (PR) and pain relief inten-
sity difference (PRID).
Despite this considerable number of outcomes, many of them 
were presented incompletely, for instance: a) upper and low lim-
its were not available to calculate the standard deviation (SD); or 
b) the results were presented in graphic form with no raw data 
available. The authors were contacted sometimes, with the aim of 
resolving these inconsistencies, but without reply. 
The studies also evaluated adverse effects, vital signs and clin-
ical laboratory tests. The adverse effects are described later on 
in this paper. The other matters that these studies assessed were 
not within the aims of the present review, which were to evaluate 
clinical outcomes relating to efficacy and safety.
As stated in the methods section, the risk of bias of each 
included study was assessed through the risk-of-bias table from 
the Cochrane Collaboration.9 The studies were classified as pre-
senting moderate risk of bias, since all the three key domains 
(sequence generation, allocation concealment and blinding) were 
considered “unclear”, as presented in Figures 2 and 3. 
Database Search strategy
Lilacs (Literatura Latino-
Americana e do Caribe 
em Ciência da Saúde)
(prexige) OR (LUMIRACOXIB) OR (LUMIRACOXIB  COX 189 ) OR (COX-189) OR (lumiracoxib) OR (COX-2 inhibitor) OR (Organic 
Chemicals) OR (Cyclooxygenase 2 Inhibitors)
(Toothache) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR (acute dental pain)
PubMed
(“prexige “[Substance Name]) OR (LUMIRACOXIB) OR (LUMIRACOXIB  COX 189 ) OR (COX-189) OR (lumiracoxib) OR (COX-2 inhibitor) 
OR (“Organic Chemicals”[Mesh]) OR (“Cyclooxygenase 2 Inhibitors “[Pharmacological Action]) or (Cyclooxygenase  Inhibitors)
AND
(“Toothache”[Mesh]) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR 
(acute dental pain) or (dental pain  postoperative)
AND
randomized controlled trial [Publication Type] OR controlled clinical trial [Publication Type] OR randomized controlled trials 
[MeSH Terms] OR random allocation [MeSH Terms] OR double blind method [MeSH Terms] OR single blind method [MeSH 
Terms] OR clinical trial [Publication Type] OR clinical trials [MeSH Terms] OR (clinical* [Text Word] AND trial* [Text Word]) OR 
single* [Text Word] OR double* [Text Word] OR treble* [Text Word] OR triple* [Text Word] OR placebos [MeSH Terms] OR 
placebo* [Text Word] OR random* [Text Word] OR research design [MeSH Terms] OR comparative study [MeSH Terms] OR 
evaluation studies [MeSH Terms] OR follow-up studies [MeSH Terms] OR prospective studies [MeSH Terms] OR control* [Text 
Word] OR prospectiv* [Text Word] OR volunteer* [Text Word]
SciELO
(prexige) OR (LUMIRACOXIB) OR (LUMIRACOXIB COX 189) OR (COX-189) OR (lumiracoxib) OR (COX-2 inhibitor) OR (Organic 
Chemicals) OR (Cyclooxygenase 2 Inhibitors)
AND
(Toothache) OR ( Toothaches) OR (Odontalgia) OR (Odontalgias) OR (acute and post-operation dental pain) OR (acute dental pain)
Table 1 - Continuation
All studies retrieved by electronic 
and manual search (n = 279)
Prospective studies on humans 
that dealt with the clinical 
conditions and intervention of 
interest (n = 10)
Prospective randomized 
controlled trials on humans that 
dealt with the clinical conditions 
and intervention of interest (n = 4)
Randomized controlled trials on 
humans that dealt with the 
clinical conditions and interven-
tion of interest (n = 3)
Studies excluded: narrative reviews, 
in vitro/in situ studies, animal and 
diagnostic studies, case reports, 
retrospective case series and studies 
not dealing with the clinical 
condition or intervention of interest 
(n = 269) 
Studies excluded: non-randomized 
controlled trials (n = 6)
Study excluded: because of use of 
data from previously published study, 
i.e. duplicated publication (n = 1)
Figure 1. Flow chart of studies, from databases to inclusion in the 
systematic review.
1. Sequence generation
Two studies that were included were considered to have a mod-
erate risk of bias.5,6 Although they were reported to be random-
ized, the method used to generate the allocation sequence was 
not presented. There was an attempt to contact their authors, but 
no reply was obtained from them. One study (Fricke et al.) was 
considered to present a low risk of bias.4 
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over-encapsulated in order to maintain blinding, dissolution tests 
were performed to confirm that there was no clinically meaningful 
effect from encapsulation on comparator dissolution. In the study 
by Fricke et al., the method used for blinding was described.4
4. Incomplete outcome data 
In the study by Kellstein et al., an intention-to-treat (ITT) analysis was 
conducted, and no dropout was reported.5 If required, patients were 
allowed to take rescue medication consisting of hydrocodone bitar-
trate/paracetamol (5 mg/500 mg) or paracetamol 1000 mg at any 
time during the 24-hour post-dose period. The time of rescue use was 
recorded, and no further efficacy evaluations were performed after-
wards. However, the number of patients who required rescue medica-
tion was not reported. In the study by Zelenakas et al., an ITT analy-
sis was also performed, and there were 145 dropouts. The reasons for 
medication and early discontinuation were presented.6
5. Selective reporting
In all three studies, the outcomes were reported incompletely. The 
study by Zelenakas et al. did not inform all the data, including the 
following outcome data: PID, PRID and SPID.6 In the study by 
Kellstein et al, the results relating to PI and PRID (which had 
been proposed in the methods section) were not reported.5 In the 
study by Fricke et al., the median time taken to attain the onset of 
analgesia was not reported for either celecoxib or the placebo.4
6. Other sources of bias 
In all the studies, there was insufficient information to assess 
whether any other important risk of bias existed or not.
Outcome measurements
Time taken to attain the onset of analgesia
This was the only efficacy outcome measurement that could be 
fully assessed. Lumiracoxib 400 mg showed a shorter time taken 
to attain the onset of analgesia than shown by lumiracoxib 100 
mg (mean difference, MD = - 15.00; 95% confidence interval, CI: 
-100.05 to 70.05; P = 0.73). The time to onset of analgesia also 
favored lumiracoxib at a dose of 400 mg, compared with celecoxib 
200 mg (MD = -11.34; 95% CI: -16.83 to -5.85; P < 0.0001) and with 
ibuprofen 400 mg (MD = -4.10; 95% CI: -19.59 to 11.39; P = 0.60). 
A statistically non-significant MD was observed between lumira-
coxib 400 mg and rofecoxib 50 mg (MD = -0.19; 95% CI: -5.82 to 
5.44; P = 0.95). In all of the studies, the median time to onset for the 
placebo could not be estimated because the number of participants 
who achieved onset was too small. In Fricke’s study, the time taken 
to attain the onset of analgesia was reported for lumiracoxib 400 
mg (38 minutes), but not for celecoxib 400 mg. The median dif-
ference in time taken to attain the onset of analgesia using lumira-
coxib could not be calculated because the authors did not report 
the CI to enable calculation of a standard deviation (SD).
Fricke et al.4 
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Figure 3. Methodological quality summary: review authors’ judgments 
about each methodological quality item for each study included.
2. Allocation concealment 
In two of the studies included, the method used by the authors 
to conceal the allocation sequence was not described in sufficient 
detail to be able to determine whether the interventions had been 
planned in advance or during registration.5,6 One study reported 
the allocation concealment method.4
3. Blinding of participants, personnel and outcome assessors 
The three studies were described as double-blind. However, in the 
trial by Zelenakas et al., there was insufficient information to allow 
judgment about the adequacy of the blinding and also, the author 
did not reply to electronic mail enquiries asking for related informa-
tion.6 The trial by Kellstein et al. was described as a double-dummy 
design in which each patient received two tablets (either lumira-
coxib or matching placebo) and one capsule (rofecoxib, celecoxib 
or matching placebo).5 Since both of the active comparators were 
Allocation concealment?
Blinding?
Incomplete outcome data addressed?
Free from selective reporting?
Free from other bias?
Yes (low risk of bias)
Methodological quality graph: review authors’ judgements about each
methodological quality item presented as percentages across all included studies.
Unclear
0% 25% 50% 75% 100%
No (high risk bias)
Adequate sequence generation?
Figure 2. Risk of bias in included studies.
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The graph presented in Figure 4 shows the median time 
taken for onset of analgesia (primary efficacy outcome).
Use of rescue medication
One study reported the number of patients who had required res-
cue medication within 12 hours.5 The number of patients who had 
required rescue medication was lower in all the active treatment 
groups than in the placebo group (92.0%) (risk ratio, RR = 0.25; 
95% CI: 0.08 to 0.84; P = 0.03). Similar proportions of patients 
in the lumiracoxib 100 mg group (74.5%) and ibuprofen 400 mg 
group (72.5%) required rescue medication (RR = 1.03; 95% CI: 
Mean dierence
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Figure 4. Median time taken to attain the onset of analgesia.
0.81 to 1.3; P = 0.82). This proportion was numerically lower in 
the lumiracoxib 400 mg group (44.0%) (RR = 0.59; 95% CI: 0.42 
to 0.84; P = 0.003).
The time elapsed before rescue medication was required was 
significantly longer in all of the active treatment groups than in 
the placebo group (median time = 12 hours; P < 0.001), while the 
time elapsed before rescue medication was required for lumira-
coxib 400 mg (median time = 12 hours) was significantly longer 
than for lumiracoxib 100 mg (median time = 7 hours; P < 0.01) 
and ibuprofen 400 mg (median time = 8 hours; P < 0.01), as pre-
sented in Figure 4.
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Adverse events
All the clinical trials presented information on the number of 
patients with one or more adverse events. Twenty-four hours 
after intake, Kellstein et al. reported an adverse event rate of 
21/101 patients with lumiracoxib 400 mg and 9/51 with placebo 
(RR = 1.18; 95% CI: 0.58 to 2.38; P = 0.2).5 Twelve hours after 
intake, Zelenakas et al. reported a rate of 1/50 (2%) with lumira-
coxib 400 mg and 10/50 with placebo (RR = 0.1; 95% CI: 0.01 
to 0.75; P = 0.02).6 Twenty-four hours after intake, Fricke et al. 
reported a rate of 18/156 with lumiracoxib 400 mg and 9/52 with 
placebo (RR = 0.67; 95% CI: 0.32 to 1.39; P = 0.8).4
There was only one withdrawal in one study.6 This patient had 
been allocated to an ibuprofen group and presented postoperative 
bleeding at the suture site, but no association with the drug was 
reported. There was only one serious adverse event, in a patient who 
had received placebo, who presented deep vein thrombosis (DVT).6
The adverse events were generally described as mild to moder-
ate in severity. Most of them were probably related to the patients’ 
postoperative status. It is noteworthy that none of the studies 
included reported any cases of kidney failure. More details about 
other adverse events are shown in Table 2.
DISCUSSION
This study, based on analysis of the clinical trials that had been 
included in it, showed that lumiracoxib 400 mg was more effec-
tive when used for acute dental pain and postoperative pain than 
were placebo, lumiracoxib 100 mg, celecoxib 200 mg or ibupro-
fen 400 mg for the following outcomes: time taken to attain the 
onset of analgesia and time elapsed before rescue medication was 
required. There was no difference in relation to rofecoxib 50 mg. 
With regard to adverse events, this review included short-term 
trials, which only allowed assessment of acute effects. Moreover, 
the limited sample size was unhelpful for this type of analysis.
To our knowledge, this is the only systematic review assessing 
the efficacy and safety of lumiracoxib in relation to this issue. This 
review protocol was started at a time when lumiracoxib was avail-
able in several countries for many inflammatory or painful symp-
toms. However, some months later, the market scenario for lumira-
coxib changed such that this medication only remained in current 
use in three countries: Mexico, Ecuador and the Dominican Repub-
lic. Moreover, it was withdrawn from several countries such as Bra-
zil, Canada, the United Kingdom and Australia because of impor-
tant adverse effects that had been correlated with its use.11-13
With regard to the implications for research on single-dose 
drugs for treating pain, clinical trials with methodology that is 
appropriate for consistent evaluation are recommended. 
By using a sensitive search strategy, 279 articles were found. 
Among them, four articles met the inclusion criteria. It should be 
noted that one of the four articles selected was excluded (study 
by Schnitzer et al.)10 because it used data from a study previously 
published (Zelenakas et al.).6
The results from clinical trials may, in practice, be limited. 
This can be seen from the study by Zelenakas et al., in which 57 
patients (28.2%) completed the study out of 202 patients who had 
been randomized.6 Even though a patient loss of 71.8% was dem-
onstrated, this study was included in the present review.
Regarding the results from continuous variables, the overall 
effect measured only by comparing the means after the treatment 
may not be representative of the sample. This might be consid-
ered to be a limitation of the studies included in this review. The 
ideal would be to compare the groups as either the percentage 
of patients who showed improvements in values (after dichoto-
mizing the continuous variable) or the mean difference achieved 
(improvement) by each intervention group after the treatment. 
Through these statistical analyses, it would be possible to obtain 
the relative risk and the number need to treat, which would cer-
tainly be more useful in clinical practice. 
The lack of data limits some of the results from this review. The 
study by Fricke et al. did not provide SD values, or even the CI values 
(which could be used to obtain SD values indirectly) for the ‘median 
Adverse Events Lumiracoxib 
400 mg % (n/N)
Lumiracoxib 
100 mg % (n/N)
Rofecoxib 
50 mg % (n/N)
Celecoxib 
200 mg % (n/N)
Celecoxib 
400 mg % (n/N)
Ibuprofen 
400 mg % (n/N)
Placebo % 
(n/N)
Deep vein thrombosis 0 (0/50) 0 (0/51) _ _ _ 0 (0/51) 2 (1/50)
GI  signs and symptoms* 9 (27/307) 4 (4/51) 12 (12/102) 11 (20/101) 11(17/156) 8 (5/51) 14 (21/153)
Dizziness (excluding vertigo) 4 (10/257) _ 1 (1/102) 4 (4/101) 2 (3/156) _ 4 (4/103)
Vomiting 7 (17/257) _ 5.9 (6/102) 5.9 (6/101) 3 (5/156) _ 10 (10/103)
Headache 4 (9/257) _ 0 (0/102) 4 (4/101) 6 (9/156) _ 5 (5/103)
Increased sweating 1 (1/101) _ 0 (0/102) 2 (2/101) _ _ 2 (1/51)
Abdominal pain 2 (2/101) _ 1 (1/102) 0 (0/101) _ _ 0 (0/51)
Dyspnea 0 (0/101) _ 0 (0/102) 0 (0/101) _ _ 2 (1/51)
Feeling jittery
Syncope
Pyrexia
1 (1/101) _ 0 (0/102) 0 (0/101) _ _ 2 (1/51)
0 (0/156) _ _ _ 1 (1/156) _ 0 (0/0)
1 (1/156) _ _ _ 0 (0/156) _ 0 (0/0)
Total number of patients 
with any adverse event
13 (41/307) 14 (7/100) 12 (12/102) 20 (20/101) 11 (17/156) 10 (5/51) 18 (28/153)
Table 2. Adverse events
n = number of patients who presented the event; N = number of patients; GI = gastrointestinal; *such as nausea, emesis and diarrhea.
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time taken to attain the onset of analgesia’ outcome.4 Hence, it was 
not possible to pool this study in the graph presented in Figure 4.
These studies presented moderate risk of bias, according to 
the Cochrane Collaboration’s tool for assessing the risk of bias, 
which relates to moderate risk of uncertainty among the results 
available. Indeed, many of the efficacy outcomes proposed in the 
methods section of each study were not adequately presented in 
the results section, which led to notable reporting bias. Despite 
this, the present review can be considered to be the best current 
evidence so far developed to try to answer the questions: Does 
lumiracoxib present efficacy with regard to acute postoperative 
dental pain? Is it safe for this setting?
With regard to implications for further research on adverse event 
profiles, there is a lack of long-term studies, given that the duration of 
acute treatment is short or limited. Lumiracoxib use is time-limited 
or restricted, since this medication today is only marketed in three 
countries. Hence, it will be difficult to find further and better evi-
dence regarding efficacy and safety. Moreover, it can be highlighted 
that the incomplete data presentation was an important barrier pre-
venting strong statistical findings. Such barriers may be a consider-
able source of bias, and this needs to be avoided in further studies. 
With regard to implications for practice, considering the 
results from this review, there is some evidence, with a moder-
ate risk of bias, that lumiracoxib can be recommended for treat-
ing acute postoperative dental pain. Dental surgeons need a 
drug that has a rapid analgesic effect, in order to rehabilitate and 
restore their patients’ quality of life quickly and convincingly. 
This medication should be prescribed for a short period of time 
and only be used to treat acute postsurgical pain. However, the 
adverse effects are not fully known and dental professionals need 
to have enough evidence to choose the best drug for treating their 
patients and, especially, not to jeopardize their safety. 
CONCLUSIONS
There is evidence, with a moderate risk of bias, that lumiracoxib 
can be recommended for treating acute postoperative dental 
pain. However, the adverse effects are not fully known. Given that 
this drug is currently available in only three countries, further 
research is likely to be rare and discouraged. 
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